Chiesi to Acquire KalVista in $1.9B Rare Disease Deal
PARMA, ITALY & FRAMINGHAM, MASSACHUSETTS, April 29, 2026 Chiesi Group has announced a definitive agreement to acquire KalVista Pharmaceuticals...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PARMA, ITALY & FRAMINGHAM, MASSACHUSETTS, April 29, 2026 Chiesi Group has announced a definitive agreement to acquire KalVista Pharmaceuticals...
SOUTH SAN FRANCISCO, CALIFORNIA, April 30, 2026 IDEAYA Biosciences has announced that the U.S. Food and Drug Administration (FDA)...
